Ontrak (OTRK) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 13, 2018
Document Information [Line Items]
Entity Registrant Name	CATASYS, INC.
Entity Central Index Key	1,136,174
Trading Symbol	cats
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		16,135,956
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 4,855	$ 4,779
Receivables, net of allowance for doubtful accounts of $0 and $476, respectively	2,391	511
Prepaids and other current assets	628	366
Total current assets	7,874	5,656
Long-term assets
Property and equipment, net of accumulated depreciation of $1,747 and $1,542, respectively	314	612
Deposits and other assets	291	336
Total Assets	8,479	6,604
Current liabilities
Accounts payable	441	980
Accrued compensation and benefits	1,205	1,177
Deferred revenue	5,031	2,914
Other accrued liabilities	1,973	578
Total current liabilities	8,650	5,649
Long-term liabilities
Long term debt, net of discount of $535 and $0, respectively	7,415
Deferred rent and other long-term liabilities		25
Capital leases		2
Warrant liabilities	124	30
Total Liabilities	16,189	5,706
Stockholders' (deficit)/equity
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 16,087,186 and 15,889,171 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	2	2
Additional paid-in-capital	296,506	294,220
Retained earnings	(304,218)	(293,324)
Total Stockholders' (Deficit)/Equity	(7,710)	898
Total Liabilities and Stockholders' (Deficit)/Equity	$ 8,479	$ 6,604

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Receivables, allowance for doubtful accounts	$ 0	$ 476
Property and equipment, accumulated dereciation	1,747	1,542
Long term debt, discount	$ 535	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	16,087,186	15,889,171
Common stock, shares outstanding (in shares)	16,087,186	15,889,171

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Healthcare services revenues	$ 4,369,000	$ 1,195,000	$ 9,553,000	$ 4,682,000
Operating expenses
Cost of healthcare services	3,237,000	1,664,000	8,465,000	4,361,000
General and administrative	5,120,000	2,575,000	13,298,000	8,144,000
Depreciation and amortization	59,000	47,000	229,000	131,000
Total operating expenses	8,416,000	4,286,000	21,992,000	12,636,000
Loss from operations	(4,047,000)	(3,091,000)	(12,439,000)	(7,954,000)
Other Income		16,000	40,000	44,000
Interest expense	(241,000)	(1,000)	(278,000)	(3,408,000)
Loss on conversion of note				(1,356,000)
Loss on issuance of common stock				(145,000)
Change in fair value of derivative liability				132,000
Change in fair value of warrant liability	(65,000)	(2,000)	(94,000)	1,767,000
Loss from operations before provision for income taxes	(4,353,000)	(3,078,000)	(12,771,000)	(10,920,000)
Provision for income taxes		2,000	0	4,000
Net Loss	$ (4,353,000)	$ (3,080,000)	$ (12,771,000)	$ (10,924,000)
Basic and diluted net loss from operations per share: (in dollars per share)	$ (0.27)	$ (0.06)	$ (0.80)	$ (0.30)
Basic and diluted weighted number of shares outstanding (in shares)	15,917	47,638	15,909	36,181

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net loss	$ (12,771,000)	$ (10,924,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	229,000	131,000
Amortization of debt discount and issuance costs included in interest expense	95,000	3,335,000
Issuance of stock and warrants	112,000	181,000
Loss on disposal of fixed assets	69,000
Provision for doubtful accounts		307,000
Deferred rent	(67,000)	(60,000)
Share-based compensation expense	2,024,000	191,000
Loss on conversion of convertible debenture		1,356,000
Loss on issuance of common stock		145,000
Fair value adjustment on warrant liability	94,000	(1,767,000)
Fair value adjustment on derivative liability		(132,000)
Changes in current assets and liabilities:
Receivables	(1,880,000)	36,000
Prepaids and other current assets	3,000	113,000
Deferred revenue	3,994,000	1,655,000
Accounts payable and other accrued liabilities	949,000	85,000
Net cash used by operating activities	(7,063,000)	(5,348,000)
Investing activities:
Purchases of property and equipment		(274,000)
Net cash used by investing activities		(274,000)
Financing activities:
Proceeds from the issuance of common stock and warrants		16,458,000
Proceeds from the issuance of bridge loans		1,300,000
Payments on convertible debenture		(4,363,000)
Transactions costs		(1,667,000)
Proceeds from secured promissory note	7,500,000
Debt issuance costs	(336,000)
Capital lease obligations	(25,000)	(31,000)
Net cash provided by financing activities	7,139,000	11,697,000
Net increase in cash and cash equivalents	76,000	6,075,000
Cash and cash equivalents at beginning of period	4,779,000	851,000
Cash and cash equivalents at end of period	4,855,000	6,926,000
Supplemental disclosure of cash paid
Interest
Income taxes		40,000
Supplemental disclosure of non-cash activity
Common stock issued for conversion of debt and accrued interest		7,163,000
Common stock issued upon settlement of deferred compensation to officer		1,122,000
Warrants issued in connection with A/R Facility	64,000
Warrants Issued for Services [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of stock and warrants	$ 86,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit)/Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	15,889,171			15,889,171
Balance at Dec. 31, 2017	$ 2	$ 294,220	$ (293,324)	$ 898
Adoption of accounting standard at Dec. 31, 2017			1,877	1,877
Balance at Dec. 31, 2017	$ 2	294,220	(291,447)	$ 2,775
Common stock issued for outside services (in shares)	24,000			24,000
Common stock issued for outside services		112		$ 112
Warrants issued for services		86		86
Warrants issued in connection with A/R facility		64		64
Cashless warrant exercise (in shares)	174,015
Share-based compensation expense		2,024		2,024
Net loss			(12,771)	$ (12,771)
Balance (in shares) at Sep. 30, 2018	16,087,186			16,087,186
Balance at Sep. 30, 2018	$ 2	$ 296,506	$ (304,218)	$ (7,710)

Note 1 - Basis of Consolidation

Note 1 - Basis of Consolidation and Presentation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Consolidation and Presentation We harness proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human intervention, to deliver improved member health and cost savings to health plans through integrated technology enabled treatment solutions. It is our mission to provide access to affordable and effective care, thereby improving health and reducing cost of care for people who suffer from the medical consequences of behavioral health conditions; helping these people and their families achieve and maintain better lives. The accompanying unaudited condensed consolidated financial statements for Catasys, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10 not not may 10 December 31, 2017, December 31, 2017, Our ability to fund our ongoing operations is dependent on increasing the number of members that are eligible for our solutions by signing new contracts, identifying more eligible members in existing contracts, and generating fees from existing and new contracts and the success of management’s plan to increase revenue and continue to control expenses. We currently operate our On Trak twenty-two 2018. Management’s Plans In June 2018 $7.5 $5.0 $2.5 not $5.0 three November 30, 2018. August 2018, $2.5 three $5.0 November 30, 2018. June 2018, $2.5 85% not Historically we have seen and continue to see net losses, net loss from operations, negative cash flow from operating activities, and historical working capital deficits as we continue through a period of rapid growth. These conditions raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not first nine 2018. second 2019. twelve not All inter-company transactions have been eliminated in consolidation.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Revenue Recognition Revenue from contracts with customers is recognized when, or as, we satisfy our performance obligations by transferring the promised goods or services to the customers. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service. A performance obligation may i.e. not third The following table disaggregates our revenue by contract: Three Months Ended Nine Months Ended (in thousands) September 30, 2018 September 30, 2018 Revenue Percentage Revenue Percentage Commercial $ 2,635 60% $ 5,893 62% Government 1,734 40% 3,660 38% $ 4,369 100% $ 9,553 100% Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis, an upfront case rate, or fee for service based on enrolled members. The Company’s performance obligation is satisfied over time as the On Trak September 30, 2018. Cost of Services Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our third third Trak Cash Equivalents and Concentration of Credit Risk We consider all highly liquid investments with an original maturity of three may September 30, 2018, $4.4 For the nine September 30, 2018, five 86% 26%, 23%, 15%, 11%, 11% three 66% 27%, 22%, 17% For the three September 30, 2018, one 12% Basic and Diluted Income ( Loss ) per Share Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock and dilutive common equivalent shares outstanding during the period. Common equivalent shares, consisting of 3,641,785 1,795,246 nine September 30, 2018 2017, Share-Based Compensation Our 2017 “2017 2,333,334 243,853 2010 “2010 August 2018, 2017 1,400,000 “2017 422A 2017 no ten three five September 30, 2018, 3,641,785 390,880 335,402 2017 Share-based compensation expense was $1.1 $2.0 three nine September 30, 2018, $32,000 $191,000 2017, Stock Options – Employees and Directors We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations. For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our consolidated statements of operations for the three nine September 30, 2018 2017 There were 1,167,957 1,810,264 three nine September 30, 2018 no 2017. nine September 30, 2018 Weighted Avg. Shares Exercise Price Balance December 31, 2017 1,885,383 $ 11.46 Granted 1,810,264 7.50 Cancelled (53,862 ) 17.76 Balance September 30, 2018 3,641,785 $ 9.40 The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three nine September 30, 2018 2017, No. 107 110 As of September 30, 2018, $6.3 2017 3.94 Stock Options and Warrants – Non-employees We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends. For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method. There were no three nine September 30, 2018 2017. There was no three nine September 30, 2018 2017. There were 0 24,000 three nine September 30, 2018, 90,000 2017. There were 9,720 June 2018 4 In September 2018, 250,002 174,015 $0.0001, There were 1,795,246 2,011,528 September 30, 2018 2017, Common Stock There were 0 24,000 three nine September 30, 2018, 0 28,985 2017. In September 2018, 250,002 174,015 $0.0001, In April 2017, 3,125,000 $4.80 $4.464 April 28, 2017. $15.0 Pursuant to the underwriting agreement with Joseph Gunnar, we granted the underwriters a 45 468,750 May, 303,750 $1.5 In connection with the public offering, our common stock began trading on the NASDAQ Capital Market (“NASDAQ”) under the symbol “CATS” beginning on April 26, 2017. In April 2017, one hundred 100% 2,982,994 $1.4 six June 30, 2017. In April 2017, $1.1 233,734 $83,807 In April 2017, 1 6 six one not No All stock options and warrants to purchase common stock outstanding and our Common Stock reserved for issuance under the Company's equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by six six Income Taxes We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of September 30, 2018. not September 30, 2018. 740, not not We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% may 50% no September 30, 2018 Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between ( 1 2 three three Level Input: Input Definition: Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date. Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following table summarizes fair value measurements by level at September 30, 2018 Balance at September 30, 2018 (Amounts in thousands) Level I Level II Level III Total Certificates of deposit 71 - - 71 Total assets 71 - - 71 Warrant liabilities - - 124 124 Total liabilities - - 124 124 Financial instruments classified as Level III in the fair value hierarchy as of September 30, 2018, Warrant Liabilities The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three nine September 30, 2018: Level III Warrant (Dollars in thousands) Liabilities Balance as of December 31, 2017 $ 30 Issuance of warrants - Change in fair value 94 Balance as of September 30, 2018 $ 124 Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two seven five seven Variable Interest Entities Generally, an entity is defined as a Variable Interest Entity (“VIE”) under current accounting rules if it has (a) equity that is insufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (b) equity investors that cannot make significant decisions about the entity’s operations, or that do not As discussed under the heading Management Services Agreement not third not Based on the design and provisions of this MSA and the working capital loans provided to the entities, we have determined that TIH and CIH are a VIE’s, and that we are the primary beneficiary as defined in the current accounting rules. Accordingly, we are required to consolidate the revenues and expenses of the managed medical corporation. Management Services Agreement In April 2018, July 2018, not ● general administrative support services; ● information systems; ● recordkeeping; ● billing and collection; ● obtaining and maintaining all federal, state and local licenses, certifications and regulatory permits. All clinical matters relating to the operation of TIH and CIH and the performance of clinical services through the network of providers shall be the sole and exclusive responsibility of the TIH and CIH Board free of any control or direction by Catasys. TIH and CIH pay us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the medical group, provided that any capitalized costs will be amortized over a five 10% 15% Under the MSA’s, the equity owner of the affiliated treatment center has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We also agree to provide working capital loans to allow for TIH and CIH to pay for their obligations. Substantially all of the activities of TIH and CIH either involves us or are conducted for our benefit, as evidenced by the facts that (i) the operations of TIH is conducted primarily using our licensed protocols and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the treatment center. Payment of our management fee is subordinate to payments of the obligations of TIH and CIH, and repayment of the working capital loans is not third not The amounts and classification of assets and liabilities of the VIE included in our consolidated balance sheets at September 30, 2018 (in thousands) September 30, 2018 Cash and cash equivalents $ 76 Accounts receivable 56 Total Assets $ 132 Accounts payable $ 6 Accrued liabilities 69 Total Liabilities $ 75 Warrant Liabilities The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions: September 30 , 2018 Expected volatility 102.90 % Risk-free interest rate 2.81 % Weighted average expected lives in years 1.54 Expected dividend 0 % We issued 11,049 April 2015 For the three nine September 30, 2018, $65,000 $94,000, $2,000 $1.8 2017, Recently Issued or Newly Adopted Accounting Standards In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 820, December 15, 2019, In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07” 505 50 718 December 15, 2018, no 606. not 2018 07 In April 2016, 2016 10, Revenue from Contracts with Customers (Topic 606 ) 2016 10” 2014 09, 2014 09, December 15, 2017. 2016 10 $1.9 January 1, 2018 ( 3 In February 2016, No. 2016 02, Leases (Topic 842 ) 2016 02” . 606, Revenue from Contracts with Customers no 2016 02 December 15, 2018, January 1, 2019, not may not fourth 2018. In June 2016, 2016 13, Financial Instruments - Credit Losses 2016 13” not first 2021. In July 2017, 2017 11, Earnings Per Share (Topic 260 ); Distinguishing Liabilities from Equity (Topic 480 ); Derivatives and Hedging (Topic 815 ): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” no no December 15, 2018, not 2017 11

Note 3 - ASC 606

Note 3 - ASC 606	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 3. 606 In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 2014 09 605 605” 605. 606 We adopted ASC 606 January 1, 2018 not January 1, 2018 2014 09 Balance at December 31, 2017 Adjustments Due to Adoption of ASC 606 Balance at Balance Sheet Liabilities Deferred revenue $ (2,914 ) $ 1,877 $ (1,037 ) Equity Retained earnings (293,324 ) 1,877 (291,447 ) In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated income statement and balance sheet for the three nine September 30, 2018 Three Months Ended September 30, 2018 As Balances Without Adoption of Effect of Change Income Statement Revenues Healthcare services revenues $ 4,369 $ 3,146 $ 1,223 Net loss (4,353 ) (5,576 ) 1,223 Nine Months Ended September 30, 2018 As Balances Without Adoption of Effect of Change Income Statement Revenues Healthcare services revenues $ 9,553 $ 6,032 $ 3,521 Net loss (12,771 ) (16,292 ) 3,521

Note 4 - Long-term Debt

Note 4 - Long-term Debt	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. Long-Term Debt In June 2018 $7.5 $5.0 $2.5 not $5.0 three November 30, 2018. August 2018, $2.5 three $5.0 November 30, 2018. Repayment of the loans is on an interest-only basis through September 1, 2019, $20.0 six June 30, 2019. 8.75% one 2.0%. 0.2% 0.4% $9,000 $10,000 three nine September 30, 2018, 6.0% March 1, 2022 3% 2% not $147,000 170,000 three nine September 30, 2018. Obligations under the Loan Agreement are secured by a first not The Loan Agreement includes customary affirmative and restrictive covenants, excluding any covenants to attain or maintain certain financial metrics, and also includes customary events of default, including for payment failures, breaches of covenants, change of control and material adverse changes. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% may 6% may In connection with the Loan Agreement, we were obligated to pay the Lender a $75,000 We recognized approximately $588,000 $49,000 $53,000 three nine September 30, 2018 Also in June 2018, $2.5 85% 3.0%. 1% two first not In connection with the A/R Facility agreement, we issued Heritage Bank of Commerce warrants to purchase an aggregate of 9,720 two $262,000 $35,000 $41,000 three nine September 30, 2018

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue from contracts with customers is recognized when, or as, we satisfy our performance obligations by transferring the promised goods or services to the customers. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service. A performance obligation may i.e. not third The following table disaggregates our revenue by contract: Three Months Ended Nine Months Ended (in thousands) September 30, 2018 September 30, 2018 Revenue Percentage Revenue Percentage Commercial $ 2,635 60% $ 5,893 62% Government 1,734 40% 3,660 38% $ 4,369 100% $ 9,553 100% Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis, an upfront case rate, or fee for service based on enrolled members. The Company’s performance obligation is satisfied over time as the On Trak September 30, 2018.
Cost of Sales, Policy [Policy Text Block]	Cost of Services Cost of healthcare services consists primarily of salaries related to our care coaches, outreach specialists and other staff directly involved in member care, healthcare provider claims payments, and fees charged by our third third Trak
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents and Concentration of Credit Risk We consider all highly liquid investments with an original maturity of three may September 30, 2018, $4.4 For the nine September 30, 2018, five 86% 26%, 23%, 15%, 11%, 11% three 66% 27%, 22%, 17% For the three September 30, 2018, one 12%
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Income ( Loss ) per Share Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of shares of common stock and dilutive common equivalent shares outstanding during the period. Common equivalent shares, consisting of 3,641,785 1,795,246 nine September 30, 2018 2017,
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation Our 2017 “2017 2,333,334 243,853 2010 “2010 August 2018, 2017 1,400,000 “2017 422A 2017 no ten three five September 30, 2018, 3,641,785 390,880 335,402 2017 Share-based compensation expense was $1.1 $2.0 three nine September 30, 2018, $32,000 $191,000 2017, Stock Options – Employees and Directors We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the consolidated statements of operations. For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our consolidated statements of operations for the three nine September 30, 2018 2017 There were 1,167,957 1,810,264 three nine September 30, 2018 no 2017. nine September 30, 2018 Weighted Avg. Shares Exercise Price Balance December 31, 2017 1,885,383 $ 11.46 Granted 1,810,264 7.50 Cancelled (53,862 ) 17.76 Balance September 30, 2018 3,641,785 $ 9.40 The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three nine September 30, 2018 2017, No. 107 110 As of September 30, 2018, $6.3 2017 3.94 Stock Options and Warrants – Non-employees We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends. For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method. There were no three nine September 30, 2018 2017. There was no three nine September 30, 2018 2017. There were 0 24,000 three nine September 30, 2018, 90,000 2017. There were 9,720 June 2018 4 In September 2018, 250,002 174,015 $0.0001, There were 1,795,246 2,011,528 September 30, 2018 2017,
Stockholders' Equity, Policy [Policy Text Block]	Common Stock There were 0 24,000 three nine September 30, 2018, 0 28,985 2017. In September 2018, 250,002 174,015 $0.0001, In April 2017, 3,125,000 $4.80 $4.464 April 28, 2017. $15.0 Pursuant to the underwriting agreement with Joseph Gunnar, we granted the underwriters a 45 468,750 May, 303,750 $1.5 In connection with the public offering, our common stock began trading on the NASDAQ Capital Market (“NASDAQ”) under the symbol “CATS” beginning on April 26, 2017. In April 2017, one hundred 100% 2,982,994 $1.4 six June 30, 2017. In April 2017, $1.1 233,734 $83,807 In April 2017, 1 6 six one not No All stock options and warrants to purchase common stock outstanding and our Common Stock reserved for issuance under the Company's equity incentive plans immediately prior to the reverse stock split were appropriately adjusted by dividing the number of affected shares of common stock by six six
Income Tax, Policy [Policy Text Block]	Income Taxes We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of September 30, 2018. not September 30, 2018. 740, not not We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% may 50% no September 30, 2018
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between ( 1 2 three three Level Input: Input Definition: Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date. Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following table summarizes fair value measurements by level at September 30, 2018 Balance at September 30, 2018 (Amounts in thousands) Level I Level II Level III Total Certificates of deposit 71 - - 71 Total assets 71 - - 71 Warrant liabilities - - 124 124 Total liabilities - - 124 124 Financial instruments classified as Level III in the fair value hierarchy as of September 30, 2018, Warrant Liabilities The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three nine September 30, 2018: Level III Warrant (Dollars in thousands) Liabilities Balance as of December 31, 2017 $ 30 Issuance of warrants - Change in fair value 94 Balance as of September 30, 2018 $ 124
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two seven five seven
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Variable Interest Entities Generally, an entity is defined as a Variable Interest Entity (“VIE”) under current accounting rules if it has (a) equity that is insufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (b) equity investors that cannot make significant decisions about the entity’s operations, or that do not As discussed under the heading Management Services Agreement not third not Based on the design and provisions of this MSA and the working capital loans provided to the entities, we have determined that TIH and CIH are a VIE’s, and that we are the primary beneficiary as defined in the current accounting rules. Accordingly, we are required to consolidate the revenues and expenses of the managed medical corporation. Management Services Agreement In April 2018, July 2018, not ● general administrative support services; ● information systems; ● recordkeeping; ● billing and collection; ● obtaining and maintaining all federal, state and local licenses, certifications and regulatory permits. All clinical matters relating to the operation of TIH and CIH and the performance of clinical services through the network of providers shall be the sole and exclusive responsibility of the TIH and CIH Board free of any control or direction by Catasys. TIH and CIH pay us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the medical group, provided that any capitalized costs will be amortized over a five 10% 15% Under the MSA’s, the equity owner of the affiliated treatment center has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We also agree to provide working capital loans to allow for TIH and CIH to pay for their obligations. Substantially all of the activities of TIH and CIH either involves us or are conducted for our benefit, as evidenced by the facts that (i) the operations of TIH is conducted primarily using our licensed protocols and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the treatment center. Payment of our management fee is subordinate to payments of the obligations of TIH and CIH, and repayment of the working capital loans is not third not The amounts and classification of assets and liabilities of the VIE included in our consolidated balance sheets at September 30, 2018 (in thousands) September 30, 2018 Cash and cash equivalents $ 76 Accounts receivable 56 Total Assets $ 132 Accounts payable $ 6 Accrued liabilities 69 Total Liabilities $ 75
Derivatives, Policy [Policy Text Block]	Warrant Liabilities The warrant liabilities were calculated using the Black-Scholes model based upon the following assumptions: September 30 , 2018 Expected volatility 102.90 % Risk-free interest rate 2.81 % Weighted average expected lives in years 1.54 Expected dividend 0 % We issued 11,049 April 2015 For the three nine September 30, 2018, $65,000 $94,000, $2,000 $1.8 2017,
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued or Newly Adopted Accounting Standards In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 820, December 15, 2019, In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07” 505 50 718 December 15, 2018, no 606. not 2018 07 In April 2016, 2016 10, Revenue from Contracts with Customers (Topic 606 ) 2016 10” 2014 09, 2014 09, December 15, 2017. 2016 10 $1.9 January 1, 2018 ( 3 In February 2016, No. 2016 02, Leases (Topic 842 ) 2016 02” . 606, Revenue from Contracts with Customers no 2016 02 December 15, 2018, January 1, 2019, not may not fourth 2018. In June 2016, 2016 13, Financial Instruments - Credit Losses 2016 13” not first 2021. In July 2017, 2017 11, Earnings Per Share (Topic 260 ); Distinguishing Liabilities from Equity (Topic 480 ); Derivatives and Hedging (Topic 815 ): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” no no December 15, 2018, not 2017 11

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended (in thousands) September 30, 2018 September 30, 2018 Revenue Percentage Revenue Percentage Commercial $ 2,635 60% $ 5,893 62% Government 1,734 40% 3,660 38% $ 4,369 100% $ 9,553 100%
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Avg. Shares Exercise Price Balance December 31, 2017 1,885,383 $ 11.46 Granted 1,810,264 7.50 Cancelled (53,862 ) 17.76 Balance September 30, 2018 3,641,785 $ 9.40
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Balance at September 30, 2018 (Amounts in thousands) Level I Level II Level III Total Certificates of deposit 71 - - 71 Total assets 71 - - 71 Warrant liabilities - - 124 124 Total liabilities - - 124 124
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Level III Warrant (Dollars in thousands) Liabilities Balance as of December 31, 2017 $ 30 Issuance of warrants - Change in fair value 94 Balance as of September 30, 2018 $ 124
Schedule of Variable Interest Entities [Table Text Block]	(in thousands) September 30, 2018 Cash and cash equivalents $ 76 Accounts receivable 56 Total Assets $ 132 Accounts payable $ 6 Accrued liabilities 69 Total Liabilities $ 75
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30 , 2018 Expected volatility 102.90 % Risk-free interest rate 2.81 % Weighted average expected lives in years 1.54 Expected dividend 0 %

Note 3 - ASC 606 (Tables)

Note 3 - ASC 606 (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Balance at December 31, 2017 Adjustments Due to Adoption of ASC 606 Balance at Balance Sheet Liabilities Deferred revenue $ (2,914 ) $ 1,877 $ (1,037 ) Equity Retained earnings (293,324 ) 1,877 (291,447 ) Three Months Ended September 30, 2018 As Balances Without Adoption of Effect of Change Income Statement Revenues Healthcare services revenues $ 4,369 $ 3,146 $ 1,223 Net loss (4,353 ) (5,576 ) 1,223 Nine Months Ended September 30, 2018 As Balances Without Adoption of Effect of Change Income Statement Revenues Healthcare services revenues $ 9,553 $ 6,032 $ 3,521 Net loss (12,771 ) (16,292 ) 3,521

Note 1 - Basis of Consolidati_2

Note 1 - Basis of Consolidation and Presentation (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Aug. 31, 2018
Corporate Finance [Member] | A/R Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,500,000	$ 2,500,000
Line of Credit Facility, Percentage of Accounts Receivable as Borrowings	85.00%	85.00%
Loan Agreement [Member]
Debt Instrument, Face Amount	$ 5,000,000	$ 5,000,000
Debt Instrument, Face Amount of Potential Additional Loan	2,500,000	2,500,000
Debt Instrument, Billings Threshold for Additional Loan	5,000,000	5,000,000
Achievement of Billing, Additional Loan, Amount			$ 2,500,000
Maximum [Member] | Loan Agreement [Member]
Debt Instrument, Face Amount	$ 7,500,000	$ 7,500,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Apr. 28, 2017USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Jun. 30, 2018shares	May 31, 2017USD ($)shares	Apr. 30, 2017USD ($)shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Jun. 30, 2018	Jun. 30, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)$ / shares
Cash, Uninsured Amount | $		$ 4,400,000				$ 4,400,000				$ 4,400,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount										3,641,785	1,795,246
Share-based Compensation, Total | $										$ 2,024,000	$ 191,000
Class or Warrant or Right, Exercised During the Period		250,002
Stock Issued During Period, Shares, Exercise of Warrants		174,015
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001				$ 0.0001				$ 0.0001			$ 0.0001
Class of Warrant or Right, Outstanding		1,795,246				1,795,246	2,011,528			1,795,246	2,011,528
Stock Issued During Period, Shares, Issued for Services						0	0			24,000	28,985
Proceeds from Issuance of Common Stock | $											$ 16,458,000
Gain (Loss) on Conversion of Debt | $											(1,356,000)
Gain (Loss) on Issuance of Common Stock | $											(145,000)
Income Tax Expense (Benefit), Total | $							2,000			0	4,000
Fair Value Adjustment of Warrants | $						65,000	$ 2,000			94,000	$ (1,767,000)
Retained Earnings (Accumulated Deficit), Ending Balance | $		$ (304,218,000)				(304,218,000)				(304,218,000)		$ (291,447,000)	$ (293,324,000)
Contract with Customer, Liability, Current | $		$ 5,031,000				$ 5,031,000				$ 5,031,000		1,037,000	$ 2,914,000
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance | $												1,877,000
Contract with Customer, Liability, Current | $												$ (1,877,000)
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio					6
Chairman and Chief Executive Officer [Member]
Deferred Salary Settled by Shares | $					$ 1,100,000
Common Stock Issued for Settlement of Deferred Salary Balance					233,734
Gain (Loss) on Issuance of Common Stock | $					$ (83,807)
Several Investors, Including Acuitas and Shamus [Member] | Convertible Debentures [Member]
Debt Conversion, Converted Instrument, Shares Issued					2,982,994
Gain (Loss) on Conversion of Debt | $									$ (1,400,000)
Public Offering [Member] | Joseph Gunnar & Co., LLC [Member]
Stock Issued During Period, Shares, New Issues	3,125,000
Shares Issued, Price Per Share | $ / shares	$ 4.80
Shares Issued, Price Per Share, Net | $ / shares	$ 4.464
Proceeds from Issuance of Common Stock | $	$ 15,000,000
Over-Allotment Option [Member] | Joseph Gunnar & Co., LLC [Member]
Stock Issued During Period, Shares, New Issues				303,750
Proceeds from Issuance of Common Stock | $				$ 1,500,000
Additional Shares Available for Purchase	468,750
Warrants Related to Investor Relations Services [Member]
Class of Warrant or Right, Issued During Period						0	90,000			24,000	90,000
Warrants Issued in Connection with A/R Facility [Member]
Class of Warrant or Right, Issued During Period			9,720
Warrants Not Subject to Amendment [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		11,049				11,049				11,049
Minimum [Member] | Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life										2 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life										5 years
Maximum [Member] | Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life										7 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life										7 years
The 2017 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,333,334				2,333,334				2,333,334
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized										1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		3,641,785				3,641,785				3,641,785
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares										390,880
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		335,402				335,402				335,402
Share-based Compensation, Total | $						$ 1,100,000	$ 32,000			$ 2,000,000	$ 191,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						1,167,957	0			1,810,264	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $		$ 6,300,000				$ 6,300,000				$ 6,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition										3 years 343 days
The 2017 Stock Incentive Plan [Member] | Nonemployees [Member]
Share-based Compensation, Total | $						$ 0	$ 0			$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						0	0			0	0
The 2017 Stock Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										3 years
The 2017 Stock Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										5 years
The 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		243,853				243,853				243,853
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Number of Major Customers						1				5
Concentration Risk, Percentage						12.00%				86.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration Risk, Percentage										26.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration Risk, Percentage										23.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Concentration Risk, Percentage										15.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Customer Four [Member]
Concentration Risk, Percentage										11.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Customer Five [Member]
Concentration Risk, Percentage										11.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers								3
Concentration Risk, Percentage										66.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration Risk, Percentage										27.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration Risk, Percentage										22.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]
Concentration Risk, Percentage										17.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 4,369	$ 1,195	$ 9,553	$ 4,682
Revenues, percentage	100.00%		100.00%
Commercial [Member]
Revenues	$ 2,635		$ 5,893
Revenues, percentage	60.00%		62.00%
Government Contract [Member]
Revenues	$ 1,734		$ 3,660
Revenues, percentage	40.00%		38.00%

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Employee and Director Stock Option Activity (Details) - Employees and Directors [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Balance, shares (in shares) | shares	1,885,383
Balance, weighted average exercise price (in dollars per share) | $ / shares	$ 11.46
Granted, shares (in shares) | shares	1,810,264
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 7.50
Cancelled, shares (in shares) | shares	(53,862)
Cancelled, weighted average exercise price (in dollars per share) | $ / shares	$ 17.76
Balance, shares (in shares) | shares	3,641,785
Balance, weighted average exercise price (in dollars per share) | $ / shares	$ 9.40

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Fair Value, Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Total assets	$ 71
Warrant liabilities	124	$ 30
Total liabilities	124
Certificates of Deposit [Member]
Certificates of deposit	71
Fair Value, Inputs, Level 1 [Member]
Total assets	71
Warrant liabilities
Total liabilities
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Certificates of deposit	71
Fair Value, Inputs, Level 2 [Member]
Total assets
Warrant liabilities
Total liabilities
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Certificates of deposit
Fair Value, Inputs, Level 3 [Member]
Total assets
Warrant liabilities	124
Total liabilities	124
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Certificates of deposit

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Using Significant Level III Inputs (Details) - Warrants [Member] - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Balance	$ 30
Issuance (exercise) of warrants, net
Change in fair value	94
Balance	$ 124

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Summary of Amounts and Classification of Assets and Liabilities of the VIE in Our Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 4,855	$ 4,779	$ 6,926	$ 851
Total Assets	8,479	6,604
Accounts payable	441	980
Total Liabilities	16,189	$ 5,706
Variable Interest Entity, Primary Beneficiary, Aggregated Disclosure [Member] | TIH [Member]
Cash and cash equivalents	76
Accounts receivable	56
Total Assets	132
Accounts payable	6
Accrued liabilities	69
Total Liabilities	$ 75

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies - Fair Value Assumptions, Warrant Liabilities (Details)	Sep. 30, 2018
Measurement Input, Price Volatility [Member]
Warrant liability assumptions	1.029
Measurement Input, Risk Free Interest Rate [Member]
Warrant liability assumptions	0.0281
Measurement Input, Expected Term [Member]
Warrant liability assumptions	1.54
Measurement Input, Expected Dividend Rate [Member]
Warrant liability assumptions	0

Note 3 - ASC 606 - Adoption of

Note 3 - ASC 606 - Adoption of ASC 606 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Deferred revenue	$ (5,031)		$ (5,031)		$ (1,037)	$ (2,914)
Retained earnings	(304,218)		(304,218)		(291,447)	$ (293,324)
Healthcare services revenues	4,369	$ 1,195	9,553	$ 4,682
Net loss	(4,353)	$ (3,080)	(12,771)	$ (10,924)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Healthcare services revenues	3,146		6,032
Net loss	(5,576)		(16,292)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Healthcare services revenues	1,223		3,521
Net loss	$ 1,223		$ 3,521
Accounting Standards Update 2014-09 [Member]
Deferred revenue					1,877
Retained earnings					$ 1,877

Note 4 - Long-term Debt (Detail

Note 4 - Long-term Debt (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Aug. 31, 2018	Dec. 31, 2017
Interest Expense, Total		$ 241,000	$ 1,000		$ 278,000	$ 3,408,000
Debt Instrument, Unamortized Discount, Total		535,000			535,000			$ 0
Heritage Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	9,720			9,720
Corporate Finance [Member] | A/R Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,500,000			$ 2,500,000
Line of Credit Facility, Percentage of Accounts Receivable as Borrowings	85.00%			85.00%
Line of Credit Facility, Commitment Fee Percentage				1.00%
Debt Instrument, Term				2 years
Debt Issuance Costs, Gross	$ 262,000			$ 262,000
Amortization of Debt Issuance Costs		$ 35,000			41,000
Prime Rate [Member] | Corporate Finance [Member] | A/R Facility [Member]
Debt Instrument, Basis Spread on Variable Rate				3.00%
Loan Agreement [Member]
Debt Instrument, Face Amount	5,000,000			$ 5,000,000
Debt Instrument, Face Amount of Potential Additional Loan	2,500,000			2,500,000
Debt Instrument, Billings Threshold for Additional Loan	5,000,000			5,000,000
Achievement of Billing, Additional Loan, Amount							$ 2,500,000
Debt Instrument, Billings Threshold for Extension					$ 20,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.75%			8.75%
Debt Instrument, Quarterly Revenue Based Payments, Percentage of Consolidated Revenue Payments when EBITDA is Negative					0.20%
Debt Instrument, Quarterly Revenue Based Payments, Percentage of Consolidated Revenue Payments when EBITDA is Positive					0.40%
Interest Expense, Total		$ 9,000			$ 10,000
Debt Instrument, Final Payment, Percent of Each Loan Tranche					6.00%
Debt Instrument, Prepayment Penalty Fee, During Interest-only Payment Period, Percent					3.00%
Debt Instrument, Prepayment Penalty Fee, After Interest-only Payment Period, Percent					2.00%
Interest Expense, Debt, Total		$ 147,000			$ 170,000
Debt Instrument, Interest Rate, Additional Default Amount		5.00%			5.00%
Debt Instrument, Late Payment Fee, Percent		6.00%			6.00%
Debt Instrument, Fee Amount		$ 75,000			$ 75,000
Debt Instrument, Unamortized Discount, Total		588,000			588,000
Amortization of Debt Discount (Premium)		$ 49,000			$ 53,000
Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Face Amount	$ 7,500,000			$ 7,500,000
Loan Agreement [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate, Threshold Percent					2.00%